Hemangiomas, localized tumors of blood vessels, appear in approximately 10-12% of Caucasian infants. These lesions are characterized by a rapid proliferation of capillaries for the first year (proliferating phase), followed by slow, inevitable, regression of the tumor over the ensuing 1-5 yr (involuting phase), and continual improvement until 6-12 yr of age (involuted phase). To delineate the clinically observed growth phases of hemangiomas at a cellular level, we undertook an immunohistochemical analysis using nine independent markers. The proliferating phase was defined by high expression of proliferating cell nuclear antigen, type IV collagenase, and vascular endothelial growth factor. Elevated expression of the tissue inhibitor of metalloproteinase, TIMP 1, an inhibitor of new blood vessel formation, was observed exclusively in the involuting phase. High expression of basic fibroblast growth factor (bFGF) and urokinase was present in the proliferating and involuting phases. There was coexpression of bFGF and endothelial phenotypic markers CD31 and von Willebrand factor in the proliferating phase. These results provide an objective basis for staging hemangiomas and may be used to evaluate pharmacological agents, such as corticosteroids and interferon alfa-2a, which accelerate regression of hemangiomas. By contrast, vascular malformations do not express proliferating cell nuclear antigen, vascular endothelial growth factor, bFGF, type IV collagenase, and urokinase. These data demonstrate immunohistochemical differences between proliferating hemangiomas and vascular malformations which reflect the [ 10-12% of Caucasian infants. These lesions are characterized by a rapid proliferation of capillaries for the first year (proliferating phase), followed by slow, inevitable, regression of the tumor over the ensuing 1-5 yr (involuting phase), and continual improvement until 6-12 yr of age (involuted phase). To delineate the clinically observed growth phases of hemangiomas at a cellular level, we undertook an immunohistochemical analysis using nine independent markers. The proliferating phase was defined by high expression of proliferating cell nuclear antigen, type IV collagenase, and vascular endothelial growth factor. Elevated expression of the tissue inhibitor of metalloproteinase, TIMP 1, an inhibitor of new blood vessel formation, was observed exclusively in the involuting phase. High expression of basic fibroblast growth factor (bFGF) and urokinase was present in the proliferating and involuting phases. There was coexpression of bFGF and endothelial phenotypic markers CD31 and von Willebrand factor in the proliferating phase. These results provide an objective basis for staging hemangiomas and may be used to evaluate pharmacological agents, such as corticosteroids and interferon alfa-2a, which accelerate regression of hemangiomas. By contrast, vascular malformations do not express proliferating cell nuclear antigen, vascular endothelial growth factor, bFGF, type IV collagenase, and urokinase. These data demonstrate immunohistochemical differences between proliferating hemangiomas and vascular malformations which reflect the biological distinctions between these vascular lesions. (J. Clin. Invest. 1994Invest. . 93:2357Invest. -2364.) Key words: hemangioma angiogenesis * basic fibroblast growth factor * growth factors * tissue inhibitors of metalloproteinase
Introduction
Hemangioma is a benign vascular lesion and is the most common tumor of infancy. The incidence is 1-2% in neonates (1) and 12% by age 1 yr (2) . Hemangioma occurs in 22.9% of premature infants with a birth weight below 1,000 g (3) . Hemangiomas are more frequent in Caucasian infants than in other racial groups. Female infants are more likely to develop hemangioma than males; the gender ratio is 3:1 (4) . Most hemangiomas appear during the first weeks oflife. The majority present as a single localized cutaneous tumor. However, hemangiomas may proliferate simultaneously in multiple sites anywhere in the body. Subcutaneous or visceral lesions may not manifest until the second to third month oflife (5) . The natural history of hemangiomas is characterized by rapid postnatal growth for [8] [9] [10] [11] [12] mo (the proliferatingphase), followed by slowbut inevitable regression for the next 1-5 yr (the involuting phase) (5) . There is complete regression of hemangiomas in over 50% of children by age 5 yr and in over 70% by age 7 yr, with continued improvement in the remaining children until 10-12 yr (the involuted phase) ( 1, 4) .
The majority of hemangiomas are minor vascular birthmarks that require no treatment. Approximately 10% of hemangiomas, however, become problematic, endangering or even life-threatening. Large lesions distort or ulcerate and destroy tissues (Fig. 1) . Even a small hemangioma may interfere with function of a vital organ, e.g., obstruction of the airway or deformation of cornea resulting in loss of vision. Multiple lesions, particularly those in the liver, or large cutaneous lesions can divert considerable blood volume and produce high output heart failure. The extensive, possibly abnormal, endothelial surface within the tumor may induce platelet trapping and a thrombocytopenic coagulopathy (Kasabach-Merritt syndrome) (6) .
The pathogenesis of hemangiomas is not well understood (5) . The tumors are composed ofmicrovessels lined by plump, mitotically active endothelial cells and pericytes (5, 7, 8) . The concept that tumors are "angiogenesis dependent," first proposed by Folkman, suggests new insights into the life cycle of hemangioma (9, 10) . Angiogenic molecules are known to act on endothelial cells and pericytes to initiate the formation of capillary networks ( 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . This process is tightly regulated by inhibitors ofendothelial cell growth which help to maintain the microvasculature in a quiescent state under physiological conditions ( 17, 18) .
Thus, hemangioma offers a unique model to study angiogenesis as a primary tumor of microvasculature in which angiogenesis is initially excessive, followed by inhibition and regression of the newly formed blood vessels. Defining the growth phases of hemangioma requires clinical observation, and there is as yet no uniform standard for these stages. Some studies of hemangioma describe phenotypic endothelial cell and pericyte markers and demonstrate the presence of mast cells in histological sections (5, (19) (20) (21) (22) (23) (24) (25) (26) (27) (22) . We carried out an immunohistochemical study of a panel of antigens in an effort to define objectively the phenotype that could distinguish the proliferating, involuting, and involuted phases of hemangiomas, and vascular malformations. We analyzed the expression of proliferating cell nuclear antigen (PCNA)' in histologic sections of surgical specimens. PCNA reflects the S phase of the cell cycle (28) . We also analyzed the angiogenic factors, vascular endothelial growth factor (VEGF) ( 14) , and basic fibroblast growth factor (bFGF) ( 16, 17) . Furthermore, we measured type IV collagenase, urokinase, and their inhibitors, i.e., tissue inhibitors of metalloproteinases (TIMP). We examined the expression of vWf, CD3 1, and a-smooth muscle cell actin (SMC-actin). Mast cells were also counted. All of these analyses were carried out on tissue sections obtained at different stages ofthe life cycle ofthe hemangioma. We also examined a small series of vascular malformations, one specimen from each ofthe major single and combined channel abnormalities. The rationale for analyzing collagenase, TIMP, and mast cells in these histologic specimens is (a) extracellular proteolysis is a necessary step in capillary formation and angiogenesis and it may be regulated by the balance between proteolytic enzymes; (b) recruitment of inflammatory cells has been reported in tumor-associated angiogenesis; and (c) mast cells have been quantitated in late proliferating and involuting hemangiomas (22, 23) . Furthermore, mast cell interactions with either fibroblasts or macrophages are observed in involuting lesions (24) .
We show here that the three clinical stages of hemangiomas are clearly separable by specific histologic markers.
Methods
Specimens. 38 hemangioma specimens were obtained from tissue removed by surgical excision in infants and children ranging from 3 wk to 15 yr of age. None of the children had been treated with corticosteroids, interferon, or other pharmacological agents. All specimens were fixed in neutralized 4% formaldehyde, dehydrated through a graded series of ethyl alcohol to absolute xylene, and embedded in paraffin. Of 38 paraffin blocks, 20 specimens were processed in our laboratory, and 18 specimens were obtained from the Department of Pathology at Children's Hospital. Three phases in the natural history of hemangioma were clinically defined: (I) the proliferating phase-the period of rapid growth, 0-12 mo; (2) the involuting phase-the period in which the lesion appears to slow its growth (proportionately to the growth of the child) and then regresses (usually by age 13-60 mo); and (3) the involuted phase-the period in which there is no further regression (after 61 mo). Vascular malformations were arterio-venous malformation, arterio-capillary-venous malformation, venous malformation, capillaryvenous malformation, and lymphatic malformation (lymphangioma). These patients were 8, 18, 11, 14, and 0.8 yr old, respectively.
Confocal microscopy. Paraffin blocks were sectioned at 500 ,m and deparaffinized with xylene followed by ethyl alcohol. Sections were stained fluorescently with Lucifer yellow CH (200 ,ug/ml) (Molecular Probes, Inc., Eugene, OR) and embedded in Spurr plastic (Ernest F. Fullam, Inc., Latham, NY) as described previously (29) . The embedded tissue was then examined at a magnification of 40 using a confocal laser scanning microscope (Sarastro 2000; Molecular Dynamics, Inc., 1. Abbreviations used in this paper: Ab, antibody; bFGF, basic fibroblast growth factor; PCNA, proliferating cell nuclear antigen; SMC-actin, a-smooth muscle cell actin; TBS, Tris-buffered saline; TIMP, tissue inhibitors of metalloproteinase; VEGF, vascular endothelial growth factor. Sunnyvale, CA) fitted with a 25 mW argon-ion laser and an upright microscope (Optishot-2; Nikon Inc., Melville, NY). Serial optical sections (0.5-ytm thick) were collected at 0.5-tim step intervals and rendered in three dimensions using Voxel View Ultra software (Vital Images, Inc., Fairfield, IA) to examine the three-dimensional nature and distribution of blood vessels within the specimens.
Antibodies. Antibodies (Abs) used for this study are summarized in Table I . Anti-human PCNA murine mAb, anti-human CD3 1 murine mAb, and anti-human vWf murine mAb were purchased from Dako Corp. (Carpinteria, CA) (30) (31) (32) . Anti-human bFGF murine mAb and the epitope peptide were gifts from Takeda Chemical Industry (Osaka, Japan) (Dr. K. Igarashi) (33). Anti-guinea pig VEGF rabbit Ab was generously provided by Dr. D. Senger (Beth Israel Hospital, Boston, MA) (34, 35) . Anti-human type IV collagenase murine mAb was donated by Dr. W. G. Stetler-Stevenson (National Institutes of Health, Bethesda, MD) (36) . Anti-human urokinase murine mAb was purchased from American Diagnostica Inc. (Greenwich, CT) (37). Anti-human TIMP rabbit Ab was a generous gift from Dr. Z. Werb (University of California, San Francisco, Berkeley, CA). Anti-SMC-actin rabbit Ab was donated by Dr. I. Herman (Tufts Medical School, Boston, MA) (38) . Alkaline phosphatase-conjugated goat anti-mouse or goat anti-rabbit Ab were purchased from Promega Corp. (Madison, WI).
Immunohistochemistry. Paraffin blocks were sectioned at 6-8 gm in thickness and attached to poly-L-lysine (Sigma Chemical Co., St. Louis, MO) coated glass slides. As an internal control, two to five sections from different specimens were attached to each slide. The paraffin sections were deparaffinized by xylene and gradual ethyl alcohol and then rehydrated in Tris-buffered saline (TBS), pH 7.4. All procedures were carried out at room temperature. The sections were incubated with protease (250 ,g/ml) for 6 min (type XXIV bacterium; Sigma Chemical Co.) before staining for CD3 1, vWf, bFGF, VEGF, and type IV collagenase. Sections were then incubated with blocking buffer (TBS supplemented with 2% goat serum and 0.05% Triton X-l00) for 10 min.
Primary antibodies diluted with blocking buffers (Table I) were applied for 2 h. After incubation with primary antibodies,-alkaline phosphatase-conjugated goat anti-mouse IgG (2.5 tg/ml) or antirabbit IgG (2.0 Mg/ml) was diluted in blocking buffer or TBS alone for 2 h. The immunoreactions were visualized as bright red precipitles by incubation with the substrate, fast red chromogen (Dako Corp.). The reaction was stopped by water and counterstained with hematoxylin, and the slides were mounted in water base mounting media. The opti- 9.. at.. and tense (JA). In the involuting phase, the skin becomes grayish, and the tumor is less tense (IB). In the involuted phase, redundant skin atrophies, and fibrous fatty tissue remains (IC). From these three specimens, immunoreactivity for nine markers and mast cell staining is demonstrated (x 187). Negative control staining with goat anti-mouse IgG (2A-2C) and goat anti-rabbit IgG (3A-3C) showed no specific staining. Positive staining for the markers was visualized by alkaline phosphatase-dependent red staining against a blue nuclear counterstain, as described in Methods. PCNA staining was localized predominantly in the nuclei of pericytes ofmicrovessels in 4A, but not in 4B and 4C. VEGF staining was demonstrated in cytoplasm of both endothelial cells and pericytes of microvessels in SA, but not in 5B and SC. Type IV collagenase staining was localized in the cytoplasm ofendothelial cells lining microvessels in 6A, but not in 6B and 6C. bFGF staining was observed in the cytoplasm of endothelial cells lining microvessels in 7A and 7B, but not in 7C. Urokinase staining was seen predominantly in nuclei and cytoplasm of pericytes (8A-8C 
Results
Correlation ofexpression ofPCNA, VEGF, and typeIVcollagenase with theproliferatingphase ofhemangioma. Antibodies to PCNA, VEGF, and type IV collagenase preferentially stained sections from hemangiomas in the proliferating phase. PCNA is a nuclear antigen expressed maximally in the S phase of the cell cycle. Formation of tubes, branches, and capillary networks as demonstrated in the confocal image (Fig. 3 ) depends on division of pericytes and endothelial cells. Only rarely did these cells stain positively for PCNA in lesions defined as involuting or involuted phases. A representative specimen from each phase is shown in Fig. 2, 4A . The proliferating phase where PCNA staining localized in nuclei ofpericytes and some endothelial cells is compared with nearly undetectable specific staining in sections from the involuting phase (Fig. 2, 4B ) and the involuted phase (Fig. 2, 4C ). The highest number of PCNA-stained microvessels was observed in the sections from proliferating lesions compared with sections taken in the other rowth phases. There were statistically significant differences among the three phases of hemangioma (Fig. 4) . Staining for VEGF (a specific mitogen for endothelial cells) was localized predominantly within the cytoplasm of pericytes and endothelial cells ofthe microvessels during the proliferating phase (Fig.  2, SA) . No immunoreaction was observed in sections from the involuting or involuted phases (Fig. 2, SB or SC) . Overall AN-OVA for these markers between the three groups indicated that the difference was significant (Fig. 4) . A similar staining pattern to that observed for PCNA and VEGF was seen when type IV collagenase staining was analyzed for all samples from the three groups (Fig. 2, 6A-6C and Fig. 4) . Staining of metalloproteinase, a type IV collagenase, was localized in proliferating phase lesions as seen in a representative section (Fig. 2, 6A) .
bFGF (an angiogenic polypeptide) staining was observed within the cytoplasm of endothelial cells lining microvessels in both the proliferating and involuting phases (Fig. 2, 7A and 7B), but not in sections from involuted tissue (Fig. 2, 7C ). The expression ofbFGF was significantly higher in the proliferating phase as compared with the involuted phase (Fig. 4) .
Urokinase, CD3 1, and vWf failed to discriminate between proliferation and involution, as abundant staining was observed in sections from both of these phases in the hemangioma. Urokinase staining was localized in the nuclei and cytoplasm of pericytes and endothelial cells in sections from all phases (Fig. 2, 8A-8C ). The expression ofurokinase was significantly higher in both proliferating and involuting phases than in the involuted phase (P < 0.05, t test). CD31 and vWf were localized in endothelial cytoplasm in microvessels in sections from all three phases (Fig. 2, 9A-9C and IOA-IOC) . The expression of CD31 was significantly higher in the involuting phase than in the involuted phase (Fig. 4 , P < 0.05). The expression ofvWF was significantly higher in the combined proliferating and involuting phases than in the involuted phase (P <0.05, t test).
Correlation The results were subjected to overall ANOVA, and the significant differences among these three groups were assessed by Fisher Protected Least Significant Difference test and reported as P values.
An Immunohistochemical Analysis ofHemangiomas 2361 0 neovascularization. Thus, it is interesting that TIMP 1 expression was not observed in sections from the proliferating phase, but was readily detectable in sections from the involuting phase. Furthermore, TIMP 1 staining was localized predominantly in pericyte cytoplasm of microvessels in the involuting phase (Fig. 2, 1iB ), but not in those from the proliferating or involuted phases (Fig. 2, 11A or JJC) . Finally, the expression of TIMP was significantly higher in the involuting phase than in either the proliferating or involuted phases (Fig. 4) . SMCactin, a marker ofmature smooth muscle cells, was more prominent in involuting phase lesions than in sections from the proliferating and involuted phases. The staining was localized in the cytoplasm of pericytes in sections from all phases (Fig. 2,  12A-12C ) as well as smooth muscle cells (data not shown).
Analysis of specimens from all three groups revealed that the expression of SMC-actin was significantly higher in the involuting phase than in both the proliferating and involuted phases (Fig. 4) .
Mast cells stained by toluidine blue predominated in the early to middle involuting phase, but only scattered mast cells were observed as lesions matured (Fig. 2, 13A-13C ). The presence of mast cells was significantly greater in the involuting phase than in either the proliferating or involuted phases (Fig. 4) .
Low expression ofnine markers and mast cells in vascular malformations. The microvessels of various types of vascular malformations showed little or no immunoreactivity with all nine markers, as seen in Table II . The expression of these markers was in a range observed in the involuted phase of hemangiomas (Fig. 4) . As expected, vWf staining was observed in sections from all the classes ofvascular malformation examined. Other blood vessel markers, CD3 1 and SMC-actin, were also detected in all lesions, except venous malformation appeared not to express the CD31 antigen. Collagenase IV staining was not detected in any ofthe vascular malformations. Barely detectable bFGF, PCNA, VEGF, and urokinase staining were observed in cytoplasm ofpericytes as well as endothelial cells of microvessels in some sections (Table II) . Occa- sional mast cells were observed at a similar frequency to the involuted phase of hemangiomas (Table II and Fig. 4 ).
Confocal imaging of capillary networks in a proliferating phase hemangioma. Three-dimensional images ofa proliferating hemangioma and normal skin were reconstructed by confocal microscopy (Fig. 3) . Optical sections rendered in three dimensions were collected from the tissue block and revealed a tortuous network of disorganized microvessels (Fig. 3 A) . The sections showed crowding of new microvessels and sprouts. In contrast, microvessels in normal skin were sparse and uniform (Fig. 3 B) .
Discussion
Characterizing the life cycle of hemangioma into three phases is based solely on clinical observation. The proliferating phase, spanning the first 12 mo of age, is followed by the involuting phase ( 12-60 mo) , and the tumor is finally involuted by 12 yr ofage (5) . Although these clinical phases are useful in assessing the longitudinal changes in individual lesions, there is no standardization to permit accurate comparison between patients. This is essential to assess the efficacy of treatments directed at accelerating regression of hemangiomas.
We examined the expression ofa panel ofnine markers in a cohort of specimens from patients whose lesions had been staged clinically. Our goals were to document the three phases at the cellular level and to gain insight into the pathogenesis of hemangioma. We found that the expression of PCNA, VEGF, and type IV collagenase as well as the absence ofTIMP I distinguished proliferating phase lesions from the subsequent phases (Fig. 4) . In contrast, the involuting phase was characterized by prominent expression of TIMP I with correspondingly less expression of PCNA, VEGF, and type IV collagenase. VEGF has been implicated in angiogenesis because it specifically induces proliferation of endothelial cells and also results in increased vascular permeability ( 14, 15, (40) (41) (42) . Conspicuous expression of VEGF during the proliferating phase of hemangioma provides circumstantial evidence that this peptide may be involved in the pathogenesis of the tumor along with bFGF, another angiogenic peptide.
Interestingly, bFGF was expressed prominently throughout the first two growth phases, but was undetectable in the terminal phase ofthe cycle. bFGF staining was localized in the cytosol of endothelial cells, as described previously (43, 44) , but was not detectable in the basement membrane as has been documented in other organs, such as the cornea and the gastric mucous (45) (46) (47) . Recently, we have demonstrated high levels of bFGF in the urine of infants and children with hemangiomas (Folkman, J., T. Law, S. Connors, J. Mulliken, D. MacDonald, and R. A. B. Ezekowitz, unpublished observation).
The lack of detectable bFGF in the extracellular matrix could possibly result from its mobilization by collagenase, which is coexpressed (45) . It is also possible that bFGF in the extracellular matrix of hemangioma is below the sensitivity of the assay.
The pattern ofbFGF staining was mirrored in the endothelial cell phenotypic markers, CD3 1 and vWf. Absent or low level staining was observed in early lesions or lesions in the late involuted phase. These specimens were at the extremes of the spectrum ofthe hemangioma growth cycle. These findings suggest a progression from endothelial immaturity to maturity (CD3 1, vWf (48, 49) .
Our goal is to understand the pathophysiology of hemangiogenesis and regression. A pattern of events may be inferred from findings of this initial study (Fig. 5) . In the third trimester, immature endothelial cells that are CD3 1 and vWf negative coexist with immature pericytes. These cells maintain an embryonic proliferative capacity pre-and postnatal life. Rapid clinical growth, observed biochemically by PCNA expression, is mediated, in part, by angiogenic peptides VEGF and bFGF. It can be envisioned that proteolysis with type IV collagenase and later urokinase may be needed to provide space for the proliferating capillary network (see Fig. 3 ). Angiogenic peptides may act to induce differentiation of proliferative cells in the hemangioma. The differentiating cells signal an influx of mast cells and autocrine induction of TIMP 1 expression, thus changing the growth pattern and initiating involution. TIMP 1 is well recognized for its role as an inhibitor of endothelial invasion into yolk sac membrane and as a negative regulator of angiogenesis, presumably by inhibition ofangiogenic proteases like type IV collagenase and urokinase ( 17, 18) . Mast cells may secrete modulators that downregulate hemangiogenesis, for example interferons and transforming growth factors (50) (51) (52) . Thus, the lesion differentiates, with senescence of endothelial cells and with fibrosis and fat formation.
The results described in this report provide an objective basis for staging hemangioma. It is possible that expression of these markers may play a role in regulating the growth and regression of this tumor. Of note is that the staining pattern of vascular malformations was similar to that observed in involuted hemangioma (Table II) . These results confirm that vascular malformations do not consist ofactively proliferating blood vessels. The effect of corticosteroids (53) (54) (55) and interferon alfa-2a (56) (57) (58) (59) Age ( mons ) 
